Medicalgorithmics, a Warsaw Stock Exchange–listed leader in AI-powered cardiac diagnostic software, has reported estimated revenues of nearly PLN 7.2 million for the third quarter of 2025 — a 38% year-on-year increase. The medtech company is entering a new phase of rapid growth, driven by record sales and demand for its proprietary AI-based diagnostic algorithms, particularly in the United States, where revenues surged by 76%.
Since the beginning of 2025, Medicalgorithmics has signed 17 new contracts, including three in the U.S. market. Among them is an agreement with one of America’s largest Independent Diagnostic Testing Facilities (IDTFs) — a deal already reflected in the company’s results. Medicalgorithmics expects the new contracts to drive further revenue growth in the fourth quarter and beyond.
“The growth rates achieved in the third quarter show what a breakthrough moment we are in. Every new agreement we’ve signed involves our proprietary algorithms or software, and in the United States, 100% of our revenues now come from software sales,” said Dr. Kris Siemionow, CEO of Medicalgorithmics.
“During the quarter, we completed integration with one of the largest U.S. IDTFs, which subsequently doubled the number of diagnostic sessions performed thanks to our system upgrade. We’re focused on sustaining this momentum and aim to report similar growth rates regularly starting from Q4 this year.”
Record Performance in Key Metrics
As of September 30, 2025, the Medicalgorithmics Group estimates revenues for the third quarter at approximately PLN 7.17 million, up 38% year on year. U.S. revenues reached PLN 2.2 million, a 76% increase versus the same period in 2024.
The company also reported strong operational growth — the number of diagnostic sessions performed rose by 34% year on year to nearly 97,000.
“The integrations we’re implementing, together with the contract signed with one of the largest U.S. IDTFs and new agreements in progress, will further boost the number of diagnostic sessions using our solutions,” added Siemionow.
“In 2024, we doubled the number of sessions performed, and we expect another above-average increase this year.”
Expansion Through Strategic Partnerships
Medicalgorithmics has been expanding rapidly since early 2025, attracting new customers and reactivating former ones. The 17 contracts signed so far this year already exceed the total number signed throughout 2024.
Beyond the U.S. market, the company has also:
- Signed an agreement with a European IDTF,
- Partnered with a U.S. deep-tech company specializing in advanced materials, sensors, and artificial intelligence integration, and
- Secured its first two commercial VCAST contracts, one in Turkey and another in the strategic Scandinavian market.
These partnerships further strengthen the company’s position as a global innovator in medical AI technologies, combining advanced algorithms, data analytics, and digital diagnostics.
Looking Ahead
Medicalgorithmics’ results confirm its successful transition to a scalable, software-centric business model and highlight the growing international adoption of its AI-driven cardiac monitoring technologies. With multiple integrations underway and a growing customer base in key global markets, the company is well positioned to continue its dynamic growth trajectory in the coming quarters.
